ECONOMIC BURDEN AND TREATMENT PATTERNS FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA IN THE UNITED STATES
Author(s)
Galaznik A1, Asche CV2, Ren J2
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 2University of Illinois College of Medicine at Peoria, Peoria, IL, USA
OBJECTIVES: Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are common types of non-Hodgkin’s lymphoma, and the real-world evidence continues to be lacking for healthcare costs and utilization among DLBCL and FL patients. Our study aims to describe costs and health resource utilization, and characterize longitudinal treatment patterns among them. METHODS: A retrospective observational study was performed among adult patients with DLBCL or FL using the US MarketScan (Truven) administrative claims data from 1/1/2007 to 12/31/2015. Diagnoses of DLBCL and FL were based upon ICD-9 codes. Identifications of treatment lines involved 30 lymphoma-specific anticancer systemic agents. Direct healthcare costs and utilizations were computed in the 1-year post-diagnosis period. Generalized linear models with a gamma link were used to compare healthcare costs between therapies with and without rituximab. RESULTS: A total of 2,767 DLBCL and 5,989 FL patients received frontline therapy. Among them, the majority received treatment within 3 months after initial diagnosis (DLBCL 79.9% and FL 62.4%), and were treated with rituximab, ibrutinib, or bendamustine either alone or in combination (DLBCL 67.5% and FL 84.9%). The total healthcare costs were $15,555 and $10,192 per patient per month (PPPM) within one year following their initial diagnosis for DLBCL and FL, respectively. The medical costs were nearly twice as much as the drug costs for DLBCL patients. Both DLBCL and FL patients receiving rituximab had higher pharmacy costs but lower medical costs (p<0.001 for all). During the first year following initial diagnosis, the resource utilization (PPPM) of DLBCL patients included 0.21 inpatient admissions, 0.26 radiation therapy, 2.63 outpatient or office visits, 0.18 emergency room visits, 0.06 intensive care unit admissions, and 0.10 stem cell transplantation. FL patients occupied less health resources than DLBCL patients. CONCLUSIONS: The healthcare costs and health resources utilized were considerable in non-Hodgkin’s lymphoma, especially DLBCL patients.
Conference/Value in Health Info
2018-05, ISPOR 2018, Baltimore, MD, USA
Value in Health, Vol. 21, S1 (May 2018)
Code
PCN96
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology